Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy

Spencer, JS; Duthie, MS; Geluk, A; Balagon, MF; Kim, HJ; Wheat, WH; Chatterjee, D; Jackson, M; LI, W; Kurihara, JN; Maghanoy, A; Mallari, I; Saunderson, P; Brennan, PJ; Dockrell, HM; (2012) Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Memorias do Instituto Oswaldo Cruz, 107. pp. 79-89. ISSN 0074-0276 DOI:

Text - Published Version

Download (951kB) | Preview


Although leprosy is curable with drug treatment, the identification of biomarkers of infection, disease progression and treatment efficacy would greatly help to reduce the overall prevalence of the disease. Reliable biomarkers would also reduce the incidence of grade-2 disability by ensuring that those who are most at risk are diagnosed and treated early or offered repeated treatments in the case of relapse. In this study, we examined the reactivity of sera from lepromatous and tuberculoid leprosy patients (LPs) against a panel of 12 recombinant Mycobacterium leprae proteins and found that six proteins were strongly recognised by multibacillary (MB) patients, while only three were consistently recognised by paucibacillary patients. To better understand the dynamics of patient antibody responses during and after drug therapy, we measured antibody titres to four recombinant proteins, phenolic glycolipid-I and lipoarabinomannan at baseline and up to two years after diagnosis to investigate the temporal changes in the antibody titres. Reactivity patterns to individual antigens and decreases in antibody titres were patient-specific. Antibody titres to proteins declined more rapidly vs. those to carbohydrate and glycolipid antigens. Compared to baseline values, increases in antibody titres were observed during reactional episodes in one individual. Additionally, antibody responses against a subset of antigens that provided a good prognostic indicator of disease progression were analysed in 51 household contacts of MB index cases for up to two years. Although the majority of these contacts showed no change or exhibited decreases in antibody titres, seven individuals developed higher titres towards one or more of these antigens and one individual with progressively higher titres was diagnosed with borderline lepromatous leprosy 19 months after enrolment. The results of this study indicate that antibody titres to specific M. leprae antigens can be used to monitor treatment efficacy in LPs and assess disease progression in those most at risk for developing this disease.

Item Type: Article
Faculty and Department: Academic Services & Administration > Academic Administration
Research Centre: Centre for Maternal, Reproductive and Child Health (MARCH)
PubMed ID: 23283458
Web of Science ID: 312672800014


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item